With regard to GvHD, 22 of the 73 patients transplanted for FLT3-ITD AML could not receive maintenance due to concomitant severe GvHD requiring high-dose steroids and drugs with possible interactions with sorafenib. This evidence concerns the gene FLT3 and graft versus host disease.